Valiant Laboratories Ltd

Valiant Laborato Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Valiant Laboratories Ltd

₹ 96.5 0.10%
02 May 9:59 a.m.
valiantlabs.in BSE: 543998 NSE: VALIANTLAB
About

Incorporated in 1980, Valiant Laboratories
Ltd manufactures and deals in Pharmaceuticals and speciality chemicals[1]

Key Points

Business Overview:[1][2]
VLL is in the active pharmaceutical ingredient manufacturing business. It manufactures finished dosage forms of paracetamol API viz. Tablets, Capsules, and Other medications. Paracetamol API is a key ingredient used to treat a variety of conditions including Headache, Arthritis, Muscle Aches, Toothache, Backache, Cold, and Fever

Website BSE NSE - BE
  • Market Cap ₹ 419 Cr.
  • Current Price ₹ 96.5
  • High / Low ₹ 168 / 75.2
  • Stock P/E
  • Book Value ₹ 52.9
  • Dividend Yield 0.00 %
  • ROCE -1.69 %
  • ROE -1.70 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has low interest coverage ratio.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
87.96 70.77 89.92 51.41 59.55 40.52 30.58 18.88 21.48 35.23
77.28 60.84 81.30 47.59 60.94 46.83 35.11 21.27 28.21 34.61
Operating Profit 10.68 9.93 8.62 3.82 -1.39 -6.31 -4.53 -2.39 -6.73 0.62
OPM % 12.14% 14.03% 9.59% 7.43% -2.33% -15.57% -14.81% -12.66% -31.33% 1.76%
1.47 0.78 1.72 2.44 2.96 1.78 2.50 2.17 1.93 0.67
Interest 0.17 0.04 0.03 0.02 0.02 0.02 0.02 0.05 0.01 0.06
Depreciation 0.37 0.40 0.44 0.46 0.49 0.49 0.50 0.50 0.51 0.51
Profit before tax 11.61 10.27 9.87 5.78 1.06 -5.04 -2.55 -0.77 -5.32 0.72
Tax % 25.50% 25.51% 20.67% 26.12% 25.47% -30.75% -52.16% 31.17% 12.41% -122.22%
8.66 7.65 7.83 4.27 0.79 -3.50 -1.22 -1.01 -5.98 1.60
EPS in Rs 5.32 4.70 2.40 1.31 0.24 -0.81 -0.28 -0.23 -1.38 0.37
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
182 292 334 182 106
132 249 299 190 119
Operating Profit 50 42 35 -8 -13
OPM % 27% 15% 11% -5% -12%
1 2 5 10 7
Interest 2 0 0 0 0
Depreciation 3 2 2 2 2
Profit before tax 47 42 38 -1 -8
Tax % 35% 34% 24% -145%
31 28 29 0 -7
EPS in Rs 16.89 8.91 0.08 -1.52
Dividend Payout % 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 0%
TTM: -56%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -170%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: -39%
Return on Equity
10 Years: %
5 Years: %
3 Years: 16%
Last Year: -2%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 10 16 33 43 43
Reserves 78 55 68 193 186
1 61 60 60 60
17 49 52 28 8
Total Liabilities 106 182 213 325 298
20 22 30 32 31
CWIP 0 1 0 0 0
Investments 0 0 34 119 165
87 158 149 174 102
Total Assets 106 182 213 325 298

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024
9 2 23 49
-17 -12 -21 -183
11 6 -2 136
Net Cash Flow 4 -4 0 2

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 85 139 97 92
Inventory Days 18 25 17 22
Days Payable 37 72 62 54
Cash Conversion Cycle 66 91 52 60
Working Capital Days 103 111 106 98
ROCE % 38% 26% -2%

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94%
8.64% 7.08% 3.48% 1.89% 0.00% 0.00% 0.64%
1.76% 0.43% 0.00% 0.00% 0.00% 0.00% 0.00%
14.66% 17.54% 21.58% 23.18% 25.06% 25.06% 24.42%
No. of Shareholders 37,43415,82114,91414,24915,18915,69215,036

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings